Deng Yong-zhi, Liu Su-jian, Ma Li, Sun Zong-quan, Chen Jia-jun, Su Gang, Liu Chao, Wang Guo-hua, Ke Jun
Department of Cardiovascular Surgery, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Zhonghua Yi Xue Za Zhi. 2007 Jun 26;87(24):1713-6.
To investigate whether knockdown Pik3cb p110beta subunit by shRNA in autologous vein grafts can reduce intimal hyperplasia.
180 adult SD rats underwent carotid artery bypass graft surgery by using the autologous branch of jugular vein, and they were randomly divided into 6 equal groups: Group A (with the jugular vein grafts treated with 25% Pluronic F-127 only), Group B (with the graft treated with the plasmid encoding shRNA targeting Pik3cb p110beta subunit, pU6-Pik3cb-shRNA-1), Group C (with the graft treated with the plasmid encoding shRNA targeting Pik3cb p110beta subunit, pU6-Pik3cb-shRNA-2), Group D (with the graft treated with the half pU6-Pik3cb-shRNA-1 and pU6-Pik3cb-shRNA-2), and Group E (with the graft treated with the pGenesil-1 scramble shRNA), and Group F (with the jugular vein grafts treated with wortmannin). Specimens of jugular vein graft were harvested 1, 3, 7, 14, and 28 days after surgery to assess the neointimal hyperplasia. Another 18 rats were randomly divided into 6 equal groups as mentioned above to be used in a parallel experiment: 72 h after surgery specimens of jugular vein graft were harvested to undergo fluorescence quantitative real-time PCR and Western blotting to detect the mRNA expression of P13K p110beta subunit and the protein expression of phosphorylated Akt - phospho-Akt (Thr 308) and phospho-Akt (Ser473)-, and mTOR (Ser 2448). And another 9 rats received jugular vein grafts treated with the pGenesil-1 scramble shRNA, and on the postoperative days 1, 2, and 3 respectively 3 rats were killed to undergo fluorescence staining to detect the transfection efficacy.
The transfection rate of the plasmid pGenesil-1 was 60% in the vascular smooth muscle cells and 90% in the endothelial cells. The thickness of tunica intima 28 days after the surgery of the pU6-Pik3cb-shRNA-1, pU6-Pik3cb-shRNA-2, 1/2 (shRNA1 + shRNA2), and wortmannin groups were (34.6 +/- 2.7) microm, (39.4 +/- 2.5) microm, (36.7 +/- 2.9) microm, and (40.6 +/- 3.1) microm respectively, all significantly lower than that of the control group (61.8 +/- 4.3 microm, P < 0.05). The expression levels of phospho-Akt (Thr 308), phospho-Akt (Ser 473), and mTOR of the shRNA intervention and wortmannin groups were all down-regulated.
Knockdown of Pik3cb in interposition carotid artery branch of jugular vein grafts reduces intimal hyperplasia with the possible mechanism of downregulation of phosphatidylinositol 3-kinase signaling through Akt, with resultant decreases in VASC growth and survival. Modulation of the phosphatidylinositol 3-kinase pathway through knockdown Pik3cb may represent a novel therapy to prevent vein graft intimal hyperplasia after bypass grafting.
研究通过短发夹RNA(shRNA)敲低自体静脉移植物中Pik3cb的p110β亚基是否能减少内膜增生。
180只成年SD大鼠行颈静脉自体分支动脉搭桥手术,并随机分为6组,每组30只:A组(颈静脉移植物仅用25%的普朗尼克F - 127处理);B组(移植物用编码靶向Pik3cb的p110β亚基的shRNA的质粒pU6 - Pik3cb - shRNA - 1处理);C组(移植物用编码靶向Pik3cb的p110β亚基的shRNA的质粒pU6 - Pik3cb - shRNA - 2处理);D组(移植物用一半的pU6 - Pik3cb - shRNA - 1和pU6 - Pik3cb - shRNA - 2处理);E组(移植物用pGenesil - 1乱序shRNA处理);F组(颈静脉移植物用渥曼青霉素处理)。术后1、3、7、14和28天取颈静脉移植物标本评估内膜增生情况。另外18只大鼠按上述方法随机分为6组进行平行实验:术后72小时取颈静脉移植物标本进行荧光定量实时聚合酶链反应(PCR)和蛋白质免疫印迹法检测P13K的p110β亚基的mRNA表达及磷酸化Akt(磷酸化Akt(苏氨酸308)和磷酸化Akt(丝氨酸473))以及哺乳动物雷帕霉素靶蛋白(mTOR)(丝氨酸2448)的蛋白表达。另外9只大鼠接受pGenesil - 1乱序shRNA处理的颈静脉移植物,分别在术后第1、2和3天处死3只大鼠进行荧光染色检测转染效率。
质粒pGenesil - 1在血管平滑肌细胞中的转染率为60%,在内皮细胞中的转染率为90%。pU6 - Pik3cb - shRNA - 1组、pU6 - Pik3cb - shRNA - 2组、1/2(shRNA1 + shRNA2)组和渥曼青霉素组术后28天内膜厚度分别为(34.6±2.7)μm、(39.4±2.5)μm、(36.7±2.9)μm和(40.6±3.1)μm,均显著低于对照组(61.8±4.3)μm,P<0.05。shRNA干预组和渥曼青霉素组的磷酸化Akt(苏氨酸308)、磷酸化Akt(丝氨酸473)和mTOR的表达水平均下调。
敲低颈静脉移植物颈总动脉分支中的Pik3cb可减少内膜增生,其可能机制是通过Akt下调磷脂酰肌醇3激酶信号通路,从而减少血管生成和存活。通过敲低Pik3cb调节磷脂酰肌醇3激酶途径可能是一种预防搭桥术后静脉移植物内膜增生的新疗法。